Kornimate/medical-research-clean huggingface dataset:
a multiple health behavior change internet program for college students

Conditions: Sedentary Lifestyle; Stress, Psychological; Healthy Eating

Summary: the objective of this phase ii research is to evaluate the effectiveness of a population-based, individually tailored multiple health behavior change program for exercise, healthy eating, and stress management in a randomized trial including approximately 1,500 college students.

despite the importance of shaping a solid foundation of health behaviors early in life, college students have been understudied as a population for health promotion programs. this study represents innovative research for impacting the promotion of healthy lifestyles among college students. the objective is to develop and test a population-based, multiple health behavior change program for college students, livewell: a healthy foundation for life. the multiple behavior multimedia program will offer transtheoretical model-based (ttm) computer tailored feedback on regular exercise, fruit and vegetable consumption, and effective stress management, as well as providing access to a stage-matched dynamic web portal. the ttm is a comprehensive model that integrates ideas from several different theories and approaches to change (hence the name "transtheoretical") to explain and predict how and when individuals end high-risk behaviors or adopt healthy ones. thirty years of research has consistently demonstrated that change is a process that unfolds over time through a series of stages: precontemplation, contemplation, preparation, action, and maintenance. it matches specific principles and processes of change to each person's stage of change and guides individuals through the change process. the ttm has been applied throughout the world to behaviors such as smoking cessation, alcohol reduction, bullying prevention, weight management, and medication adherence. a primary goal of this phase ii grant is to assess the effectiveness of livewell in a randomized trial including 1680 students from 2 large universities in the u.s. students will be recruited via freshman orientation classes and will complete follow-up assessments at 6-and 12-months. effectiveness will be assessed by comparing improvements in continuous outcome measures and movement to public health criteria for each behavior. this intervention offers a cost-effective, science-based, and easily deliverable solution to improve multiple health behaviors, and overall health and well-being, of college students.

Eligibility criteria:
inclusion criteria: * enrolled as a freshmen in college * english speaking exclusion criteria: -
outcome of challenging lesions and patients treated with polymer free drug-coated stent

Conditions: Coronary Disease; Drug Eluting Stent; STEMI

Summary: length of dat (dual antiplatelet therapy) represents one of the most challenging choices for interventional cardiologist. prolonged dat reduces risk of subsequent mi (myocardial infarction) with an increase in major bleedings, consequently with a neutral effect on survival \[1\]. recently a polymer-free drug-coated coronary stent has been tested in a randomized controlled trial with only one month of dat due to its peculiar features, with an increased efficacy compared to bms (bare metal stent) and with a not negligible risk of st at one year (about 2%)\[2,3\]. the rct despite its promising design (inclusion of high risk patients like those with previous bleeding or with severe renal disease) showed a major limitation, that is: 1. patients who are often offered a biofreedom in real life, that is those with active cancer or needing major surgery or on oat (oral anticoagulation) 2. and patients with bifurcation and multivessel disease, that is those with an increased risk of st \[4\] 3. stemi patients \[5\] were underrepresented (less than 30%). consequently we performed this multicenter study to evaluate safety and efficacy of biofreedom in real life patients. poce (a composite end point of death, myocardial infarction, target lesion revascularization) and doce (cardiac death, mi-tlr and tlr) will be the primary end points, while its single components will be the secondary ones along stent thrombosis and with bleedings (barc classification). at least 12 months the leaders free (2) reported an incidence of mace of 9.4% at one year in overall patients. if there is a true difference in favour of the experimental treatment of 1.2%, then 870 patients are required to be 80% sure that the upper limit of a one-sided 95% confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a difference when compared to non selected patients of more than 2% \[5\] all patients implanting biofreedom with these prespecified analysis: 1. clinical * diabetic patients (both insulin and not insulin depenent) * requiring oral anticoagulation * on active cancer (that is requiring chemio or radio-therapy and or surgery) * requiring surgery * stemi 2. interventional * bifurcation (both provisional both 2 stents) * multivessel * ostial

our interest is to test the performance of these stents in real life patients

Eligibility criteria:
inclusion criteria: 1. clinical * diabetic patients (both insulin and not insulin depenent) * requiring oral anticoagulation * on active cancer (that is requiring chemio or radio-therapy and or surgery) * requiring surgery * stemi 2. interventional * bifurcation (both provisional both 2 stents) * multivessel * ostial exclusion 1. clinical less than 18 years old or more than 80 2. interventional last remaing vessel
rehabilitation in patients with human lymphotropic virus type i

Conditions: Human T-Lymphotropic Virus Type 1 Associated Myelopathy

Summary: in our times, it is known that approximately 5% of patients seropositive for htlv-1 may desengage a frame with several neurological disorders, which is called myelopathy associated with htlv-1, characterized for gait, decreased dynamic balance and limitation of walking independence the use of walkers, crutches as in wheelchairs. this evolution of the disease is based, above all, on muscle changes, such as inflammation of the muscles, which contributes to the attenuation of muscle capacity . in addition, muscle changes caused by htlv-1 also affect the respiratory muscles, causing a change in respiratory mechanics, which can impair alveolar ventilation and, therefore, the development of a restorative respiratory disorder, reducing total lung capacity. therefore, it is perceived the importance of offering planned rehabilitation according to the global assessment of the health status of these patients, considering their influence on activities of daily living.the focus of this study is on the weekly respiratory muscle training, as assessed by mensuration maximal inspiratory pressure, showed significant results in improving lung capacity and in this way promoting the prevention of pulmonary complications. therefore, the protocol proposed by the present study includes respiratory muscular training plus resistance exercise, assessing the impact on both the strength muscular respiratory to as peripheral muscles, through the palmar pressure test and consequent enhancement of quality life and functionality of these patients. furthermore, it will be possible to contribute to the knowledge of society and the scientific community about this theme, which is still very small in the world literature.


Eligibility criteria:
inclusion criteria: * seropositive carriers for htlv-1 with pet exclusion criteria: * lung diseases * heart disease * arterial hypertension * cognitive impairments
to determine if a lower extremity strengthening program improve quadriceps muscle strength

Conditions: Pulmonary Disease

Summary: the purpose of this study is to determine if a lower extremity strengthening program as part of pulmonary rehabilitation will improve quadriceps muscle strength, endurance and functional status as well as overall quality of life. hypothesis: 1. lower extremity resistance training as part of a pulmonary rehabilitation program will improve quadriceps strength, endurance and functional capacity. 2. lower extremity resistance training as part of a pulmonary rehabilitation program will improve quality of life in patients awaiting lung transplant.

objectives: 1. to determine if a lower extremity strengthening program as part of pulmonary rehabilitation is effective at increasing quadriceps strength when measured with a hand held dynamometer. 2. to determine the effectiveness of a lower extremity strengthening program as part of pulmonary rehabilitation for improving endurance and functional capacity as measured by the six minute walk test. 3. to determine if the lower extremity strengthening program as part of pulmonary rehabilitation improves overall quality of life as measured by the st. george's respiratory questionnaire. 4. to provide a basic framework for a larger randomized control study evaluating if a lower extremity strengthening program as part of a pulmonary rehabilitation program is more effective than a pulmonary rehabilitation program alone at improving quadriceps strength, endurance, and functional level.

Eligibility criteria:
inclusion criteria: * patients preparing for lung transplant * diagnoses included are: chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis, cystic fibrosis, or bronchiectasis exclusion criteria: * primary pulmonary hypertension * multi-organ transplant patients * re-transplant patients * patients requiring intubation greater than or equal to 7 days prior to transplant * any orthopedic condition which will prevent from participation in a lower extremity strengthening program

Keywords: lung transplant quadriceps strength quality of life patients with pulmonary disease awaiting lung transplant.
spread analysis of covid-19 outbreak in france by self-assessment web-application

Conditions: Covid19

Summary: a coronavirus pandemic began on 12/31/2019 with a first chinese patient. as of 04/04/2020, the epidemic affects more than 190 countries with more than 50 million official contaminations and 1,251,000 deaths. (univ j hopkins). this virus causes a pathology ranging from simple flu-like symptoms in 80% of cases to acute respiratory distress syndromes requiring intensive care in 5% of cases and a death rate of 1.4 to 4% of cases. viral contamination is airborne and fecal a first epidemic wave crossed france in march / april 2020 then a second in october / november with a source of contamination which began in mid-august 2020. the sources of propagation are not well known (what places, what times, what contacts...? ) in the context of the health crisis linked to the coronavirus, knowledge of the sources of propagation of this 2nd wave is an important issue to guide end of lockdown and second lockdown policies.


Eligibility criteria:
inclusion criteria: * users of the application * not having objected to the use of their data exclusion criteria: - user who does not have a complete questionnaire
study of the effects of trv130, at therapeutic and supra therapeutic doses, on qtc intervals

Conditions: Healthy

Summary: assess the electrocardiogram effects of trv130 relative to placebo at therapeutic and supratherapeutic doses.

* part a of the study will assess clinical safety data of trv130 * part b of the study will assess the effect of single dose trv130 on qtc

Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 45 inclusive. * women must be either a) post-menopausal; b) surgically sterile; c) of child-bearing potential and practicing contraception or remaining sexually inactive. * men must be willing to abstain from sperm donation from the time of screening through the follow-up visit and, if sexually active with a woman of child-bearing potential, must be protected by acceptable forms of effective contraception through the follow-up visit. exclusion criteria: * past or present diseases including, but not limited to, significant medical abnormalities including: psychiatric, neurologic, pulmonary, cardiac, gastrointestinal, genitourinary, renal, metabolic, endocrinologic or autoimmune disorders. * has previously participated in another trv130 clinical study.
oxycodone pharmacokinetics in preterm infants

Conditions: Pain

Summary: the pharmacokinetics of oxycodone is well characterized in children older than six months of age. however, only one study has been published with children younger than six months, concluding that unexplained inter-individual variability is pronounced in the youngest children. the aim of the current study was to quantify oxycodone pharmacokinetics in children ranging from preterm newborn infants to children up to two years of age.


Eligibility criteria:
inclusion criteria: * infants scheduled for surgery with planned perioperative or postoperative opioid analgesia were screened if the gestational age (ga) was at least 23 weeks and postnatal age (pna) below 2 years exclusion criteria: * he/she had allergy or hypersensitivity to oxycodone or other ingredients in the formulations or had received monoamineoxidase, cyp3a (cytochrome p450 3a enzymes) or cyp2d6 (cytochrome p450 2d6 enzyme) inhibitors during the previous month or other reason that was considered to contraindicate participation.
safety study of the rapid system for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: this is a safety study of the rapid system for acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * patients ≥18 to \<85 years old * pre stroke modified rankin scale (mrs) of ≤2 * a signed informed consent by patient or a legally acceptable representative exclusion criteria: * pre-stroke life expectancy of less than 6 months * current participation in another investigational drug or device study * pregnancy
nipple aspiration, ductal lavage, and duct endoscopy in screening women at moderate-to-high risk of developing breast cancer

Conditions: Breast Cancer

Summary: rationale: screening tests, such as nipple aspiration, ductal lavage, and breast duct endoscopy, may help doctors detect cancer cells early and plan more effective treatment for breast cancer. purpose: this clinical trial is studying how well nipple aspiration, ductal lavage, and breast duct endoscopy work in detecting cancer cells in healthy women who are at moderate-to-high risk of developing breast cancer.

objectives: primary * determine the incidence of mild or severe cellular atypia in nipple aspirate fluid of healthy women at moderate to high risk of developing breast cancer, defined by family history or prior atypical biopsy. secondary * correlate cellular atypia with breast cancer, biochemical tumor markers, growth factors, and genetic and protein markers in these participants. * determine cancer risk and incidence utilizing these methods of screening in these participants. * observe the natural history of atypia in these participants over a total of 10 years. * determine whether these techniques may serve as supplementary tools in future screening of these participants. outline: participants under 50 years of age undergo nipple aspiration every twelve months for 3 years. participants over 50 years of age undergo nipple aspiration every 18 months for 4.5 years. participants with significant cellular atypia in nipple aspirate fluid undergo ductal lavage and endoscopy. participants are followed annually for a total of 10 years. projected accrual: a total of 1,000 participants will be accrued for this study within approximately 4 years.

Eligibility criteria:
disease characteristics: * significant family history or prior atypical biopsy indicative of a moderate or high risk of developing breast cancer * no concurrent inflammatory breast cancer * hormone receptor status: * not specified patient characteristics: age * 18 to 64 sex * female menopausal status * premenopausal or postmenopausal performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * no prior allergy to emla cream or lidocaine * no severe illness that would preclude study participation * no mental illness or handicap that would preclude study compliance * no concurrent active infection or inflammation in the breast being studied * not unconscious * not pregnant * no nursing within the past 12 months prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * no prior subareolar surgery (e.g., microdochectomy or major duct excision) that may disrupt the ductal systems within 2 cm of the nipple * no prior breast implantation on proposed lavage side

Keywords: breast cancer
progressive relaxation exercises in copd

Conditions: Anxiety; Dyspnea

Summary: background: this study aimed to determine the effect of progressive relaxation exercises (pmr) on dyspnea and anxiety level in individuals with copd methods: the study was conducted in the pretest-posttest randomized-controlled trial and completed with 44 copd individuals, 22 interventions and 22 controls. pmr were applied once a day for four weeks in the intervention group in addition to the standard treatments. the control group received standard treatment.

background: this study aimed to determine the effect of progressive relaxation exercises (pmr) on dyspnea and anxiety level in individuals with copd methods: the study was conducted in the pretest-posttest randomized-controlled trial and completed with 44 copd individuals, 22 interventions and 22 controls. pmr were applied once a day for four weeks in the intervention group in addition to the standard treatments. the control group received standard treatment. for data collection questionnaire forms, patient follow-up schedules, modified borg scale (mbs), modified british medical research council dyspnea scale (mmrc), copd assessment test (cat), and beck anxiety scale were used.

Eligibility criteria:
inclusion criteria: * diagnosed with copd, * must be able to competence to answer the questionnaire questions, * must be able to communicate verbally, * over 18 years of age, * to have 2nd or 3rd grade copd according to the gold guide staging system, * to have 2 or more severe dyspnea according to the mmrc dyspnea scale, * no medication changes have been made in the last three months, * not having received pulmonary rehabilitation in the last 6 months, exclusion criteria: * to have severe psychological disorders, * to have non-copd pulmonary diseases, * to have cancer, * to have renal failure, * to have thyroid dysfunction, * to have liver dysfunction
analysis of changes in medication prescriptions after hospitalization for 4 disciplines: gerontology, diabetology, cardiology and rheumatology: medical, pharmaceutical and economic aspects

Conditions: Diabetes; Cardiac Disease; Rheumatic Diseases

Summary: the modifications of the medicinal treatments secondary to the hospitalizations have multiple reasons: reassessment of the previous treatment (conciliation), new therapeutic necessities, potential risk of iatrogeny or of drug interaction, restrictions of the therapeutic booklet, classification in reserve or hospital prescription ... these modifications are potentially generating extra costs for the health insurance and are monitored under the terms of the contract of good use. the aims of this analysis are to define the medical-pharmaceutical rationale of the treatment changes imposed by hospitalization in a university-hospital center, their influence on the security of the medical treatment of patients and their financial implications for healthcare organizations


Eligibility criteria:
inclusion criteria * patient social insured * patient belonging to the general social security scheme * patient followed in cardiology, rheumatology, geriatrics or diabetology departments no exclusion criteria
trial of different dosages' ge gen qin lian decoction in the treatment of type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug

Summary: ge gen qin lian decoction are one kind of chinese prescription, and previous study showed they had antidiabetic effects on the clinical patients and no obvious toxicity was found. the purpose of this study was to evaluate the efficacy and safety of different dosage of ge gen qin lian decoction in the treatment of type 2 diabetic patients and explore relationship of the dosage and effect and the safety of 3 dosages of ge gen qin lian decoction.

two hundred and forty primary diabetic patients will be expected to be recruited, which were divided into different groups in a randomized, doubled blind, dose-paralleled-control multi-centre clinical design. the patients were randomly taken with high-dosage(5 times of low-dosage),mild-dosage(3 times of low-dosage), low-dosage,placebo(4.5% of low dosage) by 2 times every day for 12 weeks. hemoglobin a1c (hba1c), fasting plasma glucose (fpg),postprandial 2 hours plasma glucose(2hpg),insulin(0h,1h,2h),syndrome,symptoms,body mass index (bmi),waist circumference (wc) of these groups were measured and analyzed. some safety indexes such blood and urine and stool routine examination, electrocardiogram (ecg)and liver and kidney function tests were measured and analyzed during the experiment. the treatment period is 12 week.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 2 diabetes mellitus * 30-65 years old * hba1c≥7.0%, and fpg\>7.0 mmol/l, but \ 11.1 mmol/l * informed consent has been signed * dampness and heat in spleen exclusion criteria: * the patients accepted diabetic treatment for more than a month continuously * the patients were treated by drugs in 3 week before they were given test drugs * diabetic ketosis, diabetic ketoacidosis or serious inflammation in a month * the contractive pressure \>160 mmhg or diastolic pressure \>100 mmhg * pregnant, preparing for pregnancy or breast-feeding women * mental patients * the patients whose alt or ast are \>100u/l,and bun or cr are abnormal. * the patients who have serious heart, lung, liver, kidney and brain or other primary complications * allergic persons * the patients who are attending other clinical trial * the patients who have serious diabetic complications * the patients who ever attended this clinical trial * alcohol and / or psychoactive substances, drug abuse and dependency * the person maybe loss for some reason such as work or life condition according to the investigator's judgement * the lipid-lowering or antihypertensive drug dosage and category which the patients are taking could not be kept stable * the patients who are eating some drugs or health food which can affect the body weight

Keywords: dose-response relationship, type 2 diabetes,tcm
patient journey in hospital with acute heart failure

Conditions: Heart Failure

Summary: a multicentre, prospective, observational, hospital-based registry of patients with acute heart failure (ahf) those whose care was guided by a cardiologist in turkey.

the purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests, precipitating and risk factors, management of from intensive care unit (icu) or coronary care unit to hospital discharge, length of stay in the icu and hospital, in-hospital mortality and discharge medications of hospitalized ahf patients in turkish population. the etiologies, precipitating factors, demographics, clinical characteristics, management and outcome of patients admitted in hospital with acute heart failure in turkish population will be recorded.

Eligibility criteria:
inclusion criteria: * patients \>18 years old * clinical diagnosis of acute heart failure * admitted to the participating hospitals exclusion criteria: * patients \<18 years old * patients with acute heart failure who are discharged from the emergency room without admission. * failure to obtain informed consent